THU0054 NKTR-358, A NOVEL IL-2 CONJUGATE, STIMULATES HIGH LEVELS OF REGULATORY T CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Suresh Siddhanti(Amgen (United States)), Brian L. Kotzin(Howard Hughes Medical Institute), Ihsan M. Diab, Richard Furie(Hofstra University), Christie Fanton(Nektar Therapeutics (United States)), Lin Lü(Nektar Therapeutics (United States)), R. D. Levin(Clinical Research of West Florida), Jonathan Zalevsky(Nektar Therapeutics (United States)), N. Dixit(Nektar Therapeutics (United States)), Vishala Chindalore(Pinnacle Clinical Research)
Cited by 5
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816